Investment Rating - The investment rating for H&H International Holdings is "Buy" (maintained) [1] Core Views - H&H International Holdings reported its 2025 annual performance, achieving revenue of 14.35 billion RMB, a year-on-year increase of 10% [7] - The company demonstrated resilience in its infant probiotics and nutritional products segment, with revenue stabilizing at a 2% year-on-year growth, contrasting with a decline of 32% in 2024 [7] - The management's strategic focus on long-term growth and compliance has been highlighted, particularly in the Australian and New Zealand (ANC) market, where revenue growth is expected despite a temporary contraction due to regulatory adjustments [7] Financial Summary - Total revenue projections for H&H International Holdings are as follows: 13.05 billion RMB for 2024, 14.35 billion RMB for 2025, 16.04 billion RMB for 2026, 17.97 billion RMB for 2027, and 20.07 billion RMB for 2028, with respective year-on-year growth rates of -6.28%, 9.97%, 11.76%, 12.02%, and 11.71% [1][8] - The net profit attributable to the parent company is forecasted to be -53.72 million RMB for 2024, 196.14 million RMB for 2025, 634.78 million RMB for 2026, 873.64 million RMB for 2027, and 1.12 billion RMB for 2028, reflecting significant growth rates of -109.23%, 465.11%, 223.64%, 37.63%, and 27.89% respectively [1][8] - The latest diluted EPS is projected to be -0.08 RMB for 2024, 0.30 RMB for 2025, 0.98 RMB for 2026, 1.35 RMB for 2027, and 1.73 RMB for 2028 [1][8] - The current P/E ratios are 131.66 for 2024, 36.06 for 2025, 11.14 for 2026, 8.10 for 2027, and 6.33 for 2028 [1][8]

Investment Rating - The report upgrades the investment rating to "Strong Buy" with a target price of HKD 16.00, compared to the current price of HKD 12.45 [2][8]. Core Insights - The company reported a revenue of HKD 14.354 billion for 2025, representing a year-on-year growth of 9.97%, with Q4 revenue growth of 3.4% [8]. - Adjusted EBITDA for 2025 was HKD 2.05 billion, up 5.0% year-on-year, while adjusted net profit reached HKD 664 million, a 22.7% increase [8]. - The company is expected to continue its growth trajectory in 2026, with a focus on product innovation and market expansion, particularly in the Swisse brand and high-end infant formula [8]. - The debt structure is improving, with a reduction in total debt and interest expenses, which is anticipated to enhance overall profitability [8]. Financial Performance Summary - For 2025, the company achieved an adjusted EBITDA margin of 14.3%, with a net profit margin of 4.6% [8]. - The net leverage ratio decreased from 3.99x to 3.45x, indicating a stronger balance sheet [8]. - The company expects revenue growth in 2026 to be in the high single to low double digits, with adjusted net profit margin targets around 5% [8]. Business Segment Performance - The ANC segment generated revenue of HKD 6.946 billion in 2025, growing 3.7% year-on-year, with Swisse maintaining the top market share in China and Australia [8]. - The BNC segment saw a robust revenue increase of 20.0% year-on-year, reaching HKD 5.257 billion, driven by strong growth in high-end infant formula [8]. - The PNC segment reported revenue of HKD 2.150 billion, up 9.0% year-on-year, with Zesty Paws experiencing a 12.8% growth in North America [8].

Investment Rating - The report maintains an "Outperform" rating for the company [2][6]. Core Insights - The company demonstrated resilience by turning a loss into a profit, with total operating revenue reaching RMB 14.35 billion, up 10.0% year-over-year, and a net profit attributable to shareholders of RMB 200 million, compared to a loss of RMB 50 million in the previous year [3][12]. - Adjusted comparable net profit, excluding non-recurring items, was RMB 660 million, reflecting a year-over-year increase of 22.7%, aligning with market expectations [3][12]. - The company’s three major business segments—Adult Nutrition (ANC), Maternal and Infant Nutrition (BNC), and Pet Nutrition (PNC)—showed synchronized growth, with revenue increases of 4.4%, 20.0%, and 8.7% year-over-year, respectively [4][13]. - The premiumization strategy has been effective, particularly in the BNC segment, where infant formula sales rose by 26.5%, and market share for ultra-premium infant formula increased to 17.1% [4][13]. - The company aims for high single-digit to low double-digit revenue growth in 2026, with an adjusted net profit margin target of approximately 5% and a net debt-to-equity ratio around 3x, indicating significant potential for earnings and valuation recovery [14][15]. Financial Summary - Revenue projections for 2026-2028 are RMB 15.98 billion, RMB 17.92 billion, and RMB 19.97 billion, respectively, with net profit attributable to shareholders expected to be RMB 650 million, RMB 860 million, and RMB 1.06 billion [6][15]. - The company’s gross margin improved year-over-year, driven by a higher proportion of high-end products and optimized costs, with an adjusted EBITDA margin of 14.3% and an adjusted net profit margin of 4.6% [5][14]. - Cash reserves exceeded RMB 1.7 billion, with 88% of adjusted EBITDA converted into pre-tax operating cash flow, and total liabilities decreased by over RMB 600 million, reducing the net leverage ratio from 3.99x to 3.45x [5][14].

Financial Data and Key Metrics Changes - The company's full-year revenue grew by 10.3% year-on-year, with significant increases in adjusted net profit and EBITDA [1][10] - The leverage ratio decreased from 4x in 2024 to 3.045x in 2025, indicating improved financial health [1][45] - The adjusted EBITDA margin was reported at 14.3%, with a net profit growth rate of 22.7% [10][12] Business Segment Data and Key Metrics Changes - Swisse's revenue exceeded HKD 1 billion, achieving number one position in both Mainland China and Australia [2] - The BNC business saw a 20% growth, with the super premium infant formula segment growing by 17.12% [3][12] - The PNC business accounted for 15% of total revenue, marking a new milestone, with pet supplements achieving double-digit growth [3][12] Market Data and Key Metrics Changes - China remains the largest market, contributing over 70% of revenue with a growth of 17.5% [13] - North America accounted for 12.1% of revenue, growing by 7.5%, while the ANZ market decreased by 20.2% due to strategic adjustments [14][15] - Other markets grew by 14.7% year-on-year, indicating new growth momentum [15] Company Strategy and Development Direction - The company plans to continue investing in its three business segments to enhance shareholder value and maintain a strong cash flow [4][29] - Focus on systematic innovation and consumer insights to drive product development and market expansion [6][9] - The strategy includes localization of supply chains and expansion into high-growth channels, particularly in Southeast Asia [29][30] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory for 2026, emphasizing the importance of innovation and market adaptation [28][31] - The company aims to maintain a stable SG&A ratio while continuing to invest in new channels and product categories [65] - Management acknowledged challenges from tariffs and market adjustments but remains optimistic about future performance [22][75] Other Important Information - The company maintained a dividend payout ratio of 30%, with a total dividend of HKD 0.35 per share [4][11] - The company has made significant strides in sustainability, achieving high rankings in ESG metrics [28] Q&A Session Summary Question: What has contributed to the strong growth of IMF? - Management highlighted the strong formula of the upgraded IMF and the effective market launch strategies as key factors for growth [49][50] Question: What is the expansion plan for the Southeast Asian market? - The company is focusing on Thailand, Indonesia, Singapore, and Vietnam, leveraging product innovation and local consumer insights [54][55] Question: What is the outlook for the Douyin channel and marketing expenses? - Management views Douyin as a critical channel for consumer education and sales, with plans to maintain a stable SG&A ratio while investing in new channels [60][65]

Financial Data and Key Metrics Changes - The company's full-year revenue grew by 10.3% year-on-year, with significant increases in adjusted net profit and EBITDA [1] - The leverage ratio has been reduced from 4x in 2024 to 3.045x in 2025 [1][45] - Adjusted EBITDA margin is reported at 14.3%, with adjusted net profit margin at 4.6% and net profit growth rate at 22.7% [10][32] Business Segment Data and Key Metrics Changes - Swisse revenue sales exceeded HKD 1 billion, achieving number one position in both Mainland China and Australia [2] - The BNC business saw a 20% growth, with the super premium infant formula segment achieving 17.12% growth [3] - The PNC business accounted for 15% of total revenue, marking a new milestone [3] Market Data and Key Metrics Changes - China remains the largest market, accounting for over 70% of revenue with a growth of 17.5% [13] - North America is the second largest market, contributing 12.1% of revenue with a 7.5% year-on-year growth [14] - The ANZ market accounted for 11% of revenue but saw a decrease of 20.2% due to strategic adjustments [14] Company Strategy and Development Direction - The company plans to continue investing in its three business segments to return value to shareholders and consumers [4] - Focus on systematic innovation and consumer insights to drive growth, with new product launches across various segments [6][9] - Emphasis on expanding presence in high-growth channels, including Douyin and new retail [29] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth momentum for 2026, with a focus on sustainable growth and healthy profitability [28][31] - The company aims to strengthen its leadership in core markets while expanding into new territories [29][30] - Management acknowledged challenges from tariffs and market adjustments but remains optimistic about future performance [19][22] Other Important Information - The company maintained a dividend payout ratio of 30%, with a total dividend of HKD 0.35 per share [4][11] - The company has made significant strides in sustainability efforts, achieving high rankings in ESG metrics [28] Q&A Session Summary Question: What has been done right for IMF growth and market share? - Management highlighted strong product formulation and effective market strategies, leading to over 25% growth in IMF [50] - The company has gained market share from competitors, particularly in the super premium segment, increasing from 17.1% to 19.5% [53] Question: What are the expansion plans for the Southeast Asian market? - The company is focusing on Thailand, Indonesia, Singapore, and Vietnam, leveraging product innovation and local consumer insights [55] Question: Insights on Douyin channel profitability and marketing expenses? - Management views Douyin as a crucial channel for consumer education and sales, balancing investments across various channels [61][62] - Marketing expenses are expected to remain stable while continuing to invest in new channels and product categories [66]

Financial Data and Key Metrics Changes - The company's full-year revenue grew by 10.3% year-on-year, with significant increases in adjusted net profit and EBITDA [1] - The leverage ratio decreased from 4x in 2024 to 3.045x in 2025, indicating improved financial health [1][41] - Adjusted EBITDA margin was reported at 14.3%, while adjusted net profit margin was 4.6%, with net profit growth at 22.7% [8][10] Business Segment Data and Key Metrics Changes - Swisse revenue exceeded HKD 1 billion, achieving number one position in both Mainland China and Australia, with double-digit growth in China [2] - The BNC business segment saw a 20% growth, with super premium infant formula segment growing by 17.12% [3][10] - The PNC business accounted for 15% of total revenue, marking a new milestone, with pet supplements achieving double-digit growth [3][10] Market Data and Key Metrics Changes - China remains the largest market, contributing over 70% of revenue with a growth rate of 17.5% [11] - North America accounted for 12.1% of revenue, growing by 7.5%, while the ANZ market decreased by 20.2% due to strategic adjustments [12][11] - Other markets grew by 14.7% year-on-year, contributing to overall revenue growth [13] Company Strategy and Development Direction - The company plans to continue investing in its three business segments to enhance shareholder value and maintain a strong cash flow [4] - Focus on systematic innovation and consumer insights to drive growth, with new product launches across various segments [5][6] - The strategy includes expanding into high-growth channels and markets, particularly in Southeast Asia [49][26] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth momentum for 2026, emphasizing the importance of innovation and market adaptation [25][28] - The company aims to maintain its leadership position in the Chinese market while expanding its presence in international markets [26][27] - Management acknowledged challenges from tariffs and market adjustments but remains optimistic about future profitability [20][21] Other Important Information - The company maintained a dividend payout ratio of 30%, with a total dividend of HKD 0.35 per share [4][9] - Significant improvements in cash flow conversion, with 88% of operating cash flow converted from adjusted EBITDA [9][38] - The company is committed to sustainability and ESG efforts, achieving high rankings in relevant indices [25] Q&A Session Summary Question: What has contributed to the strong growth in IMF? - Management highlighted the strong formula of the product and effective market strategies, with a focus on early-stage education and e-commerce expansion [43][44] Question: What is the expansion plan for the Southeast Asian market? - The company plans to leverage product innovation from the Chinese market and adapt to local consumer demands in Thailand, Indonesia, Singapore, and Vietnam [48][49] Question: How does the company view the profitability of the Douyin channel? - Management sees Douyin as a crucial channel for consumer education and sales, emphasizing a balanced approach to investment in various channels [52][53]

Investment Rating - The report maintains a "Buy" rating for H&H International Holdings (01112.HK) [1] Core Views - The management is actively pursuing growth strategies, indicating a clear growth ambition alongside a new product cycle, which is expected to resonate positively with the company's performance [7] - The company is projected to achieve a significant turnaround in profitability, with a forecasted net profit of 276.77 million in 2025, representing a 615.21% year-on-year increase [7] - The report highlights strong revenue growth in the BNC and infant formula segments, with expected growth rates of 20-30% for infant formula and low single-digit growth for probiotics and nutritional products [7] Financial Projections - Total revenue is forecasted to reach 14,447 million in 2025, reflecting a 10.69% year-on-year increase [1] - The adjusted EBITDA and net profit are expected to grow by 2-6% and 15-25% respectively in 2025, with an overall adjusted net profit margin projected to be in the mid-single digits [7] - The company anticipates a cash balance exceeding 1.7 billion by 2025, which will support its debt reduction efforts and optimize interest expenses in 2026 [7] Valuation Metrics - The report provides a P/E ratio forecast of 28.84x for 2025, decreasing to 9.05x by 2027, indicating an attractive valuation as earnings improve [1][7] - The projected EPS for 2025 is 0.43, with further increases to 0.99 in 2026 and 1.37 in 2027 [1]

Investment Rating - The report maintains a "Buy" rating for H&H International Holdings (01112.HK) [1] Core Views - The management is actively pursuing growth strategies, and the company is expected to enter a new growth cycle driven by product innovation and market expansion [7] - The company has shown resilience with a strong recovery in profitability, with a projected net profit of 276.77 million in 2025, a significant turnaround from a loss in 2024 [7] - The report highlights the anticipated strong growth in the BNC and infant formula segments, with expected revenue growth rates of 20-30% for infant formula and low single-digit growth for probiotics and nutritional products [7] Financial Projections - Total revenue is projected to reach 14,447 million in 2025, with a year-on-year growth of 10.69% [1] - The adjusted net profit is expected to grow significantly, with projections of 276.77 million in 2025, 637.48 million in 2026, and 882.11 million in 2027, reflecting growth rates of 615.21% and 130.33% respectively [7] - The report anticipates a gradual improvement in the company's financial metrics, including an EBITDA increase to 2,077.71 million by 2027 [8]

Core Viewpoint - The company is expected to achieve a revenue growth of 10% year-on-year in 2025, with projected revenues of 14.3 billion yuan and a net profit of 690 million yuan [1]. Group 1: Revenue Growth - All three business segments are anticipated to show strong growth in 2025. Specifically, ANC revenue is expected to grow in the mid-to-high single digits, while BNC and PNC revenues are projected to achieve low double-digit growth year-on-year [1]. - ANC segment is expected to benefit from increased demand for health products and related policy catalysts, with Swisse China projected to achieve double-digit growth in 2025. The official account indicates a 6% year-on-year increase in sales during the Double Eleven shopping festival, maintaining its position as the leader in the nutrition and health industry [1]. - BNC segment is projected to see over 20% revenue growth in 2025, primarily due to effective customer acquisition strategies, while probiotics and infant nutrition products are expected to stabilize with a significant reduction in decline [1]. - PNC segment is expected to continue double-digit growth in the U.S. market for Zesty Paws, contributing to overall PNC growth, while Solid Gold is anticipated to recover with high single-digit growth, with a narrowing decline in the U.S. market [1]. Group 2: Profitability and Margin - The EBITDA margin for 2025 is expected to align with market expectations, with ANC EBITDA margin remaining stable year-on-year. BNC EBITDA margin is projected to improve to low double digits due to sales improvements, while PNC EBITDA margin is expected to remain in the mid-single digits [2]. - Overall, the group’s EBITDA margin is anticipated to remain stable year-on-year in 2025. For 2026, ANC revenue is expected to achieve high single-digit growth, BNC revenue is projected to grow in the mid-single digits due to a high base, and PNC revenue is expected to continue double-digit growth [2]. Group 3: Profit Forecast and Valuation - The company is trading at 10-9 times the P/E ratio for 2026/2027. Given the strong performance of the milk powder segment, net profit estimates for 2025 and 2026 have been raised by 3% to 690 million yuan and 820 million yuan, respectively, with a profit forecast of 910 million yuan for 2027 [2]. - Considering the competitive nature of the industry, the target price is maintained at 17.7 HKD, corresponding to 13-11 times the P/E ratio for 2026/2027, indicating a 29% upside potential. The company maintains an outperform rating relative to the industry [2].

Core Insights - The capital market's long-term focus on Jianhe Group is shifting from historical issues to growth certainty itself, with changes in Swisse's China business being a key variable [1] Group Structure and Growth - After ten years of development, Swisse has transitioned from market introduction to a mature localized system, forming a dual growth structure of "core brand stability + sub-brand increment" [1] - This structure indicates that even with overall industry demand fluctuations, the group's core business possesses certain defensive characteristics while retaining upward elasticity [1] Financial Performance and Market Response - Swisse's continuous growth in the Chinese market provides more solid performance support for the group's book goodwill [1] - Since 2025, Jianhe Group's stock price has increased by over 40%, significantly outperforming previous market expectations [1] Valuation and Investor Focus - The recovery is not driven by sentiment but is based on a gradually clearer growth structure and improved business predictability [1] - The systematic operation of Swisse has shifted Jianhe Group's valuation logic from "repair hypothesis" to "data validation" [1] - For investors, the focus will shift from short-term growth rates to whether this structure can be sustained, if sub-brands can consistently contribute incrementally, and whether systemic advantages can further translate into profitability [1]